title: [Estimation of efficacy of Hexalyse used for the treatment of acute pharyngitis].
abstract: The objective of the present study was to elucidate the relationship between the activity of the interferon system at the local level and the frequency of the development of relapses of acute inflammation of pharyngeal mucosa. The secondary objective was to estimate the possibility, necessity, and efficacy of the correction of the abnormal local immune response with the use of immunomodulatory agents. A total of 45 patients presenting with acute pharyngitis were available for the examination. They were allocated to two groups comprised of 25 and 20 patients respectively. Those in group 1 were given Hexalyse, a composite preparation for the local application. The patients of group 2 were treated with Strepsils. The study included general and specialized otorhinological examination as well as the evaluation of interferon production at the local level by measuring (using immunoenzyme assay) the concentration of interferon-alpha in the saliva before and on days 3 and 5 after the initiation of therapy. It was shown that the adaptive mechanisms of pharyngeal mucosa in acute pharyngitis are realized through activation of the interferon system. Elimination of the inflammatory process was accompanied by normalization of interferon-alpha level in the saliva regardless of the therapeutic modality used. One third of the patients presenting with acute pharyngitis suffered insufficiency of interferon production. It is concluded that the inclusion of an immunomodulatory agent, such as Hexalyse, in the combined treatment of such patients activates biosynthesis of interferon-alpha and leads to the reduction in the frequency of relapses of the disease. The results of the study of the relationship between the concentration of interferon-alpha in the saliva, the duration of acute pharyngitis, and the frequency of its post-treatment relapses were used to develop the practical recommendations for the prescription of Hexalyse for the treatment of patients with this pathology.
mesh_terms: D000208:Acute Disease; D000328:Adult; D000779:Anesthetics, Local / Q000008:administration & dosage*; D000890:Anti-Infective Agents / Q000008:administration & dosage*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D006034:Glycyrrhetinic Acid / Q000008:administration & dosage*; D006801:Humans; D016898:Interferon-alpha / Q000187:drug effects* / Q000378:metabolism; D008012:Lidocaine / Q000008:administration & dosage*; D009113:Muramidase / Q000008:administration & dosage*; D010612:Pharyngitis / Q000188:drug therapy* / Q000473:pathology; D012463:Saliva / Q000378:metabolism; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000779:Anesthetics, Local; D000890:Anti-Infective Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D016898:Interferon-alpha; C526824:Strepsils; D008012:Lidocaine; D009113:Muramidase; D006034:Glycyrrhetinic Acid